HLA (A-B-C and-DRB1) alleles and brain MRI changes in multiple sclerosis: A longitudinal study

Genes and Immunity

Volumn 12, Issue 3, 2011, Pages 183-190

  Liguori, M ^a,b   Healy, B C ^c   Glanz, B I ^c   Khoury, S J ^c   Moscufo, N ^a   Weiner, H L ^c   De Jager, P L ^c,d   Guttmann, C R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

brain MRI; brain parenchymal fraction; genotype phenotype correlation; HLA alleles; multiple sclerosis; T2 weighted lesion volume

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HLA TYPING; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALLELES; BRAIN; CHILD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 79955484744     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.58     Document Type: Article

References (39)

1. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121. (Pubitemid 32201673)
2. Bhat R, Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009; 64: 123-132.
3. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76. (Pubitemid 44466355)
4. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000; 55: 140-148. (Pubitemid 30103439)
5. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862. (Pubitemid 47347319)
6. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991; 38: 1-15.
7. Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005; 77: 454-467. (Pubitemid 41192651)
8. Rioux JD, Goyette P, Vyse TJ, Hammarstrom L, Fernando MM, Green T et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci USA 2009; 106: 18680-18685.
9. Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007; 14: 835-840. (Pubitemid 47108189)
10. Ramagopalan SV, Deluca GC, Degenhardt A, Ebers GC. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008; 201: 183-199.
11. Vasconcelos CC, Fernandez O, Leyva L, Thuler LC, Alvarenga RM. Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis. J Neuroimmunol 2009; 214: 101-103.
12. Zivadinov R, Uxa L, Zacchi T, Nasuelli D, Ukmar M, Furlan C et al. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 2003; 250: 1099-1106. (Pubitemid 37152560)
13. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009; 132: 250-259.
14. Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D et al. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009; 66: 1531-1536.
15. Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A et al. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 2007; 79: 521-535.
16. Healy BC, Liguori M, Tran D, Chitnis D, Glanz BI, Wolfish C et al. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010; 75: 634-640.
17. Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A et al. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 2009; 209: 123-130.
18. Wu JS, James I, Qiu W, Castley A, Christiansen FT, Carroll WM et al. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmunol 2010; 219: 109-113.
19. Johnston DT, Schroeder HW. B-cell numbers in the blood of patients with non-HLA*B8 or non-HLA*B44 common variable immunodeficiency. Ann Allergy Asthma Immunol 2007; 98: 163-167. (Pubitemid 46214222)
20. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 2007; 25: 3090-3100. (Pubitemid 46482739)
21. Silva-Ramirez B, Vargas-Alarcon G, Granados J, Burgos-Vargas R. HLA antigens and juvenile onset spondyloarthritides: negative association with non-B27 alleles. Clin Exp Rheumatol 2005; 23: 721-723. (Pubitemid 41300722)
22. DeLuca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007; 104: 20896-20901.
23. Ramagopalan SV, Morris AP, Dyment DA, Herrera BM, DeLuca GC, Lincoln MR et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 2007; 3: 1607-1613. (Pubitemid 47510254)
24. Bergamaschi L, Leone MA, Fasano ME, Guerini FR, Ferrante D, Bolognesi E et al. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun 2010; 11: 173-180.
25. Chao MJ, Barnardo MC, Lincoln MR, Ramagopalan SV, Herrera BM, Dyment DA et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2008; 105: 13069-13074.
26. Gregersen JW, Kranc KR, Ke X, Svendsen P, Madsen LS, Thomsen AR et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006; 443: 574-577. (Pubitemid 44527292)
27. Ramagopalan SV, Ebers GC. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 2009; 72: 566-567.
28. Traherne JA. Human MHC architecture and evolution: implications for disease association studies. Int J Immunogenet 2008; 35: 179-192. (Pubitemid 351678693)
29. Comabella M, Fernandez-Arquero M, Rio J, Guinea A, Fernandez M, Cenit MC et al. HLA class I and II alleles and response to treatment with interferon-beta in relapsingremitting multiple sclerosis. J Neuroimmunol 2009; 210: 116-119.
30. De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008; 70: 1113-1118. (Pubitemid 351464768)
31. Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermuller J, Stadler PF et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83: 219-227.
32. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
33. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
34. Montalban X, Tintore M, Swanton J, Barkhof F, Fazekas F, Filippi M et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2009; 74: 427-434.
35. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452. (Pubitemid 14237132)
36. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
37. Glanz BI, Holland CM, Gauthier SA, Amunwa EL, Liptak Z, Houtchens MK et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007; 13: 1004-1010. (Pubitemid 351541435)
38. Wei X, Warfield SK, Zou KH, Wu Y, Li X, Guimond A et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging 2002; 15: 203-209. (Pubitemid 34112912)
39. Liu L, Meier D, Polgar-Turcsanyi M, Karkocha P, Bakshi R, Guttmann CR. Multiple sclerosis medical image analysis and information management. J Neuroimaging 2005; 15: 103S-107S.